Lung CancerNCT07220096
Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes
An observational study of Lung Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
The goal of this research study is to learn about: The effect of enrolling in the YOLC program on patient satisfaction with care provided, The needs of patients younger than 50 with lung cancer and their family, and The impact of participating in peer support networks on these patients. Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Lung Cancer
- What is being tested?
- Survey
- How many people
- 75 participants
- Where
- 1 siteUnited States
- Study dates
- 25 Sep 2025to 31 May 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Study population: MD Anderson
Who may be able to join
- Age greater than 18 years and under 50 years
- Histologic confirmation of NSCLC
- Able to complete an English-language survey independently or with the assistance of a native-language interpreter
- Pregnant women- may be enrolled due to age range of subjects. (Low risk)
Who cannot join
- Medical, psychiatric, cognitive, or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the study protocol or to complete the study.
- The following special patient population will be excluded from study group:
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- Cognitively-impaired adults
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030
Eric Singhi, MD, 713-745-2263, eksinghi@mdanderson.org
Eric Singhi, MD
About this study
The goal of this research study is to learn about:
The effect of enrolling in the YOLC program on patient satisfaction with care provided,
The needs of patients younger than 50 with lung cancer and their family, and
The impact of participating in peer support networks on these patients.
Read the detailed description
Primary Objectives:
- To determine whether enrollment in a dedicated program (YOLC) results in improved patient satisfaction with care provided.
- To characterize the distinct needs of patients under age 50 diagnosed with lung cancer as well as those of their families, and how these needs may change over time throughout the care pathway.
- To evaluate the impact of participation in peer support networks and whether it has a beneficial effect on the primary and secondary endpoints.
Secondary Objectives:
- To determine whether enrollment in a dedicated program (YOLC) results in improved patient satisfaction with care provided.
- To characterize the distinct needs of patients under age 50 diagnosed with lung cancer as well as those of their families, and how these needs may change over time throughout the care pathway.
- To evaluate the impact of participation in peer support networks and whether it has a beneficial effect on the primary and secondary endpoints.
- Overall survival, defined by time from diagnosis to death from any cause
- Clinical trial enrollment, defined by participation in any therapeutic clinical trial related to lung cancer treatment after diagnosis
- Completion of multi-disciplinary consultations, defined by patients completing consultations with at least one other specialist other than a thoracic medical oncologist or thoracic surgeon from time of initial consultation for the YOLC Program
- Quality of life, as defined by FACT-LUNG
- Financial toxicity, as defined by patient-reported financial burden, including out-of-pocket costs, insurance coverage issues, and impact of overall financial well-being (measured using validated financial toxicity scale such as COST-FACIT
- Conditions
- Lung Cancer
- Being tested
- Survey
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SurveyOther
Participants will complete an intake survey and repeat surveys at the following time points:
- Baseline
- 3 months
- 6 months
- 9 months
- 12 months
- 18 months
- 24 months
- 36 months
- 48 months
- 60 months
| Study group | Role | What they receive |
|---|---|---|
| Assessment of Patients with Young-Onset Lung Cancer | This is a registry trial enrolling participants with NSCLC diagnosed and histologically confirmed prior to the age of 50 years identified. Each participant will participate in an intake survey as well as periodic recurring surveys to provide feedback to the YOLC Program, to elucidate the individual participant's care needs, and to assess changes in personal goals, wellness, financial impact, and family support over time Receives: Other: Survey |
What is being measured
The primary outcome is the main question the study is designed to answer.
Participant satisfaction with care
Assessed via validated survey instruments (e.g., FACT-L, COST-FACIT).
- Focus on detecting even small changes in survey responses over time (baseline, 3, 6, 9, 12 months, etc.).
Measured: Through study completion; an average of 5 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Oct 2025
- Study start25 Sep 2025
- Primary completion31 May 2029 (estimated)
- Study completion31 May 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 75 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Eric Singhi, MD, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07220096
- Sponsor's protocol ID
- 2025-0646
- Other IDs
- NCI-2025-07304
- Status last verified
- Oct 2026
- First submitted
- 30 Sep 2025
- Last updated
- 6 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes
- ClinicalTrials.gov ID
- NCT07220096
- Acronym / sponsor ID
- 2025-0646
- Conditions
- Lung Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 75 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 25 Sep 2025 (actual)
- Primary completion
- 31 May 2029 (estimated)
- Study completion
- 31 May 2031 (estimated)
- First posted
- 23 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this research study is to learn about:
The effect of enrolling in the YOLC program on patient satisfaction with care provided,
The needs of patients younger than 50 with lung cancer and their family, and
The impact of participating in peer support networks on these patients.
Detailed description
Primary Objectives:
- To determine whether enrollment in a dedicated program (YOLC) results in improved patient satisfaction with care provided.
- To characterize the distinct needs of patients under age 50 diagnosed with lung cancer as well as those of their families, and how these needs may change over time throughout the care pathway.
- To evaluate the impact of participation in peer support networks and whether it has a beneficial effect on the primary and secondary endpoints.
Secondary Objectives:
- To determine whether enrollment in a dedicated program (YOLC) results in improved patient satisfaction with care provided.
- To characterize the distinct needs of patients under age 50 diagnosed with lung cancer as well as those of their families, and how these needs may change over time throughout the care pathway.
- To evaluate the impact of participation in peer support networks and whether it has a beneficial effect on the primary and secondary endpoints.
- Overall survival, defined by time from diagnosis to death from any cause
- Clinical trial enrollment, defined by participation in any therapeutic clinical trial related to lung cancer treatment after diagnosis
- Completion of multi-disciplinary consultations, defined by patients completing consultations with at least one other specialist other than a thoracic medical oncologist or thoracic surgeon from time of initial consultation for the YOLC Program
- Quality of life, as defined by FACT-LUNG
- Financial toxicity, as defined by patient-reported financial burden, including out-of-pocket costs, insurance coverage issues, and impact of overall financial well-being (measured using validated financial toxicity scale such as COST-FACIT
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Assessment of Patients with Young-Onset Lung Cancer | – | Other: SurveyThis is a registry trial enrolling participants with NSCLC diagnosed and histologically confirmed prior to the age of 50 years identified. Each participant will participate in an intake survey as well as periodic recurring surveys to provide feedback to the YOLC Program, to elucidate the individual participant's care needs, and to assess changes in personal goals, wellness, financial impact, and family support over time |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- MD Anderson
Key inclusion criteria (4 listed)
- Age greater than 18 years and under 50 years
- Histologic confirmation of NSCLC
- Able to complete an English-language survey independently or with the assistance of a native-language interpreter
- Pregnant women- may be enrolled due to age range of subjects. (Low risk)
Key exclusion criteria (5 listed)
- Medical, psychiatric, cognitive, or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the study protocol or to complete the study.
- The following special patient population will be excluded from study group:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SurveyParticipants will complete an intake survey and repeat surveys at the following time points: * Baseline * 3 months * 6 months * 9 months * 12 months * 18 months * 24 months * 36 months * 48 months * 60 months | Other | Assessment of Patients with Young-Onset Lung Cancer |
Primary outcome
Participant satisfaction with care
Time frame: Through study completion; an average of 5 year
Assessed via validated survey instruments (e.g., FACT-L, COST-FACIT). • Focus on detecting even small changes in survey responses over time (baseline, 3, 6, 9, 12 months, etc.).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2026.
- MD Anderson Cancer Center WebsiteLink provided by the sponsor.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Eric Singhi, MD principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Eric Singhi, MD (713-745-2263, eksinghi@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Participant satisfaction with care (time frame: Through study completion; an average of 5 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.